Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Repligen Corp’s stock clocked out at $111.43, down -1.84% from its previous closing price of $113.52. In other words, the price has decreased by -$1.84 from its previous closing price. On the day, 0.64 million shares were traded. RGEN stock price reached its highest trading level at $113.92 during the session, while it also had its lowest trading level at $111.15.
Ratios:
To gain a deeper understanding of RGEN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 59.17. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 8.59. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.
On June 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $150.
Wolfe Research Upgraded its Peer Perform to Outperform on April 29, 2025, while the target price for the stock was maintained at $160.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 15 ’25 when Hunt Anthony sold 26,447 shares for $123.71 per share. The transaction valued at 3,271,688 led to the insider holds 109,854 shares of the business.
Hunt Anthony bought 26,447 shares of RGEN for $3,394,208 on May 15 ’25. On Mar 17 ’25, another insider, Hunt Anthony, who serves as the Director of the company, sold 26,756 shares for $152.51 each. As a result, the insider received 4,080,663 and left with 136,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 6268784640 and an Enterprise Value of 6245995520. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.30 while its Price-to-Book (P/B) ratio in mrq is 3.04. Its current Enterprise Value per Revenue stands at 9.268 whereas that against EBITDA is 49.392.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.07, which has changed by -0.31880426 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is -9.16%, while the 200-Day Moving Average is calculated to be -19.64%.
Shares Statistics:
It appears that RGEN traded 827.24K shares on average per day over the past three months and 1082310 shares per day over the past ten days. A total of 56.25M shares are outstanding, with a floating share count of 53.19M. Insiders hold about 5.46% of the company’s shares, while institutions hold 101.91% stake in the company. Shares short for RGEN as of 1752537600 were 3398315 with a Short Ratio of 4.11, compared to 1749772800 on 3391049. Therefore, it implies a Short% of Shares Outstanding of 3398315 and a Short% of Float of 8.1599995.
Earnings Estimates
Repligen Corp (RGEN) is presently subject to a detailed evaluation by 17.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.5, with high estimates of $0.57 and low estimates of $0.45.
Analysts are recommending an EPS of between $1.77 and $1.65 for the fiscal current year, implying an average EPS of $1.69. EPS for the following year is $2.18, with 18.0 analysts recommending between $2.38 and $1.87.
Revenue Estimates
In the current quarter, 17 analysts expect revenue to total $182.07M. It ranges from a high estimate of $185.7M to a low estimate of $180M. As of the current estimate, Repligen Corp’s year-ago sales were $154.87MFor the next quarter, 17 analysts are estimating revenue of $193.2M. There is a high estimate of $200.5M for the next quarter, whereas the lowest estimate is $185.04M.
A total of 19 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $734.8M, while the lowest revenue estimate was $716.62M, resulting in an average revenue estimate of $726.63M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $826.21M in the next fiscal year. The high estimate is $850M and the low estimate is $789.14M.
